An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.
RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $84.00.
The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...
This report explores the benefits and challenges of NHS-industry partnerships aiming to catalyse improvements in the health ...
Fintel on MSN2d
Wolfe Research Initiates Coverage of Gilead Sciences (GILD) with Outperform RecommendationFintel reports that on November 15, 2024, Wolfe Research initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a ...
Gilead Sciences, a Bay Area-headquartered biotech and pharmaceutical company, is laying off 104 workers in Foster City, with ...
On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...
January, come a year after the drugmaker slashed 7 percent of the workforce at Kite Pharma, its cell therapy business.
Gilead Sciences, Inc. (GILD) Reported a 37.45% Operating Margin Last Year—What’s the Real Story?
On Thursday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $92.11 which represents a decrease of $-0.52 or -0.56% from the prior close of $92.63. The stock opened at $92.31 and ...
There was also a 65% relative reduction in COVID-related medical visits (95% CI 24.4-83.8) with nirmatrelvir-ritonavir versus ...
Insights speaks directly to the people with an inside track on the big issues. Here, Dan Glass demands pharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback